## STZ: Constellation Brands, Inc. - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_20 -3.6% below STRENGTH zone (4.0-10.0%); PEG 1.58 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-7.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($128.12)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Neutral (Bullish: 0, Bearish: 1)

**1. Faruqi & Faruqi Reminds Constellation Brands Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 21, 2025 - STZ**
- Source: TMX Newsfile | 20251218T090852 | Bearish | Relevance: 100%
- Faruqi & Faruqi, LLP is reminding Constellation Brands (NYSE: STZ) investors of a pending class action lawsuit with a lead plaintiff deadline of April 21, 2025. The lawsuit alleges that Constellation Brands made false and misleading statements regarding its fiscal year 2024 results and 2025 financial outlook, which led to a significant stock price decline after the announcement of disappointing Q3 FY25 results. Investors who purchased securities between April 11, 2024, and January 8, 2025, are encouraged to contact the law firm to discuss their legal options.

**2. Is Constellation Brands Inc Gaining or Losing Market Support?**
- Source: Sahm | 20251217T041046 | Somewhat-Bearish | Relevance: 100%
- Constellation Brands Inc's (NYSE: STZ) short interest has increased by 5.71% since its last report, with 10.51 million shares sold short, representing 6.29% of its float. This rise in short interest suggests a more bearish market sentiment towards the stock. While high short interest can sometimes indicate a potential short squeeze, traders should be aware of this growing bearish sentiment.

**3. Assenagon Asset Management S.A. Purchases 2,408 Shares of Mettler-Toledo International, Inc. $MTD**
- Source: MarketBeat | 20251219T090843 | Neutral | Relevance: 62%
- Assenagon Asset Management S.A. increased its stake in Mettler-Toledo International, Inc. by 13.7% in the third quarter, purchasing an additional 2,408 shares to now own 19,935 shares valued at approximately $24.47 million. The company's Q3 earnings beat estimates, with a reported EPS of $11.15 against a consensus of $10.62 and revenues of $1.03 billion. Analyst ratings are mixed, with several recent upgrades to "Buy" and new "Neutral" or "Equal Weight" initiations, leading to an average target price of $1,441.67.

**4. Q2 EPS Estimates for Ingersoll Rand Raised by Zacks Research**
- Source: MarketBeat | 20251218T123625 | Neutral | Relevance: 59%
- Zacks Research has raised its Q2 2026 EPS estimate for Ingersoll Rand (NYSE:IR) to $0.83 and projects FY2026 EPS at $3.37, exceeding the consensus of $3.32. The stock holds a "Hold" rating despite mixed analyst opinions on price targets. Shares are currently trading near $78, following a recent earnings report that saw the company miss EPS estimates by $0.01 but beat revenue expectations with 5.1% year-over-year growth.

**5. Biogen stock rated Outperform by RBC Capital with $210 price target**
- Source: Investing.com Canada | 20251218T213939 | Neutral | Relevance: 59%
- RBC Capital has reiterated an Outperform rating and $210 price target for Biogen (NASDAQ:BIIB), naming it a top large-cap pick for 2026 due to stabilization in its base business and expected growth from Leqembi. The firm also highlighted Biogen's expanding immunology and inflammation portfolio, which includes the early-stage BTK degrader BIIB145 for multiple sclerosis, and suggested significant upside potential linked to upcoming Eli Lilly Alzheimer's data. Biogen also recently announced collaborations and promising data for other treatments, despite a recent downgrade by HSBC due to royalty stream concerns.

### Analyst Activity

**Target Signal:** BEARISH (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Jefferies | $154 | $170 | -9% |
| 2025-11-21 | Piper Sandler | $135 | $155 | -13% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Jefferies | down | Hold |
| 2025-11-21 | Piper Sandler | main | Neutral |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.0% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 10.5% (+3.2%)
- Berkshire Hathaway, : 7.7% (0.0%)
- Blackrock Inc.: 6.1% (-2.0%)
- Capital World Invest: 3.8% (-43.3%)
- State Street Corpora: 3.8% (-4.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-7.9% 5d) with bearish MACD, trend may be turning.
2. Long-term trend broken: trading 16.2% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.58 elevated, pricing in significant growth expectations. Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bearish (6 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $23.5B |
| Beta | 0.46 |
| 52W Range | $126.45 - $229.07 |
| Short Interest | 6.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.58 |
| Forward P/E | 10.9 |
| Current P/E | 11.8 |
| YoY Growth | 7.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 4.3% to -3.6% (-7.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.6pp (needs >4.0% for momentum thesis). AM_20 at -3.3% indicates price below own 20MA trend. Underperforming sector by 3.3pp, stock-specific weakness. Below SMA200 (0.84x), long-term trend not supportive. MACD histogram bearish (-0.76), momentum weakening. RSI neutral at 42. OFD pattern: -SUH (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.58% (CS: 17) | Weak |
| RSI_14 | 42.4 | Neutral |
| MACD Histogram | -0.76 | Bearish |
| vs SMA20 | 0.967x | Below |
| vs SMA50 | 0.990x | Below |
| vs SMA200 | 0.838x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $135.00
- **Stop Loss:** $128.12 (5.1% risk)
- **Target:** $141.88 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 174
- **Position Value:** $23,490.00
- **Portfolio %:** 23.49%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-01-07 (Est: $2.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.41 | $3.63 | +6.5% |
| 2025Q2 | $3.29 | $3.22 | -2.3% |
| 2025Q1 | $2.27 | $2.63 | +15.9% |
| 2024Q4 | $3.31 | $3.25 | -1.9% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*